Concepedia

Stacey M. Frumm

SM

Statistics

Publications

9

Citations

1.2K

H-Index

9

Active since

2012

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Broad Institute

Massachusetts Institute of Technology

University of California, San Francisco

Stacey M. Frumm is an author at Dana-Farber Cancer Institute specializing in molecular oncology, medicine, and oncology.

Publications per year

2012–2020

9

Publications

9

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Alexandre Puissant, Stacey M. Frumm, Gabriela Alexe et al. · Cancer Discovery · 2013 · 633 citations · Full text

Medicine, Cancer Biology, Oncology +16

Targeting MTHFD2 in acute myeloid leukemia

Yana Pikman, Alexandre Puissant, Gabriela Alexe et al. · The Journal of Experimental Medicine · 2016 · 165 citations · Full text

Medicine, Cancer Biology, Oncology +17

Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation

Stacey M. Frumm, Zi Peng Fan, Kenneth N. Ross et al. · Chemistry & Biology · 2013 · 114 citations · Full text

Medicine, Oncology, Pharmacology +4

The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia

Versha Banerji, Stacey M. Frumm, Kenneth N. Ross et al. · Journal of Clinical Investigation · 2012 · 104 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in <i>ALK</i>-mutated neuroblastoma

Nathan F. Moore, Anna M. Azarova, Namrata Bhatnagar et al. · Oncotarget · 2014 · 80 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 9